View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIndiva 과거 순이익 실적과거 기준 점검 0/6Indiva은 연평균 6.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 42.1%의 비율로 증가했습니다.핵심 정보6.77%순이익 성장률19.56%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률42.15%자기자본이익률n/a순이익률-11.83%최근 순이익 업데이트31 Mar 2024최근 과거 실적 업데이트공시 • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024공시 • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024공시 • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023공시 • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023공시 • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023모든 업데이트 보기Recent updates공시 • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.공시 • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.공시 • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.공시 • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024공시 • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.공시 • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024공시 • Feb 28Indiva Limited announced that it expects to receive CAD 4.312 million in fundingIndiva Limited announce a non-brokered private placement of up to 30,800,000 units at a price of CAD 0.14 per unit for aggregate gross proceeds of up to CAD 4,312,000 on February 28, 2024. Each unit will consist of one common share and one-half common share purchase warrant. Each warrant will be exercisable into one common share at a price of CAD 0.15 per common share for a period of 36 months from the date of issuance. The closing of the offerings may take place in one or more tranches. The offerings are subject to certain conditions including, but not limited to, the approval of the TSXV. The company may pay certain eligible finders a finder's fee of up to CAD 400,000.공시 • Jan 22Indiva Limited announced that it expects to receive CAD 4 million in fundingIndiva Limited announces private placement of minimum of 20,000,000 units and maximum of 40,000,000 Units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 2,000,000 incase of minimum offering and CAD 4,000,000 incase of maximum offering on January 22, 2024. Each Unit consists of one common share and one-half Common Share purchase warrant. Each Warrant is exercisable into one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance. The Warrants will be governed by the terms and conditions set forth in the certificates representing the Warrants. The transaction is expected to close the final tranche closing will occur no later than March 7, 2024. The company will pay finder's cash fee 8% of the gross proceeds raised in respect of the Offering from subscribers and also issue to eligible finders such number of finder warrants equal to 8.0% of the number of Units sold under the Offering to subscribers introduced by such finders to the Company. The Finder Warrants, to the extent they are issued, shall entitle the holder thereof to acquire one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance.공시 • Nov 22Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023Indiva Limited provided revenue guidance for fourth quarter of 2023. The company expects fourth quarter of 2023 net revenue, excluding contract manufacturing, to improve sequentially driven by new product introduction, including first full quarter of No Future sales across Canada. New SKUs coming to market include additional No Future gummies and vapes, Blips, as well as new 5-count and 25-count Pearls gummies. Gross margins are expected to continue to trend higher over time as the Company benefits from a mix shift to higher margin products and continues to achieve further production efficiencies driven by greater utilization of automation in production and packaging activities.공시 • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023공시 • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023공시 • Aug 11Indiva Limited Launches No Future Gummies and VapesIndiva Limited introduced a new value-focused cannabis brand called No Future, which the Company has already begun shipping to B.C. and Alberta and is expected to ship to Ontario in September 2023. No Future is intended to fill a large and critical gap in the cannabis marketplace that opened once the ingestible extracts market was eliminated earlier this year. Indiva expects No Future to accelerate the migration of consumers from the illicit market to the legal market by drastically reducing the price per milligram of THC in cannabis edibles and other extract products such as vapes. No Future will initially launch with four flavours of THC gummies and three varieties of 1.2g 510 vapes. No Future THC Gummies will be 10mg THC per pack and retail prices are expected to reset the floor price of legal market gummies across Canada, with some stores selling at similar prices per mg of THC as ingestible extracts were sold. No Future Vapes will be sold in 1.2g 510 thread cartridges and introduced in three great-tasting strains: Sour Tangie (Sativa), Cherry Zlushie (Hybrid), and Hot CKS (Indica). Similar to No Future gummies, Indiva expects this set of products to reset the floor price of legal 1.2g vapes across Canada. B.C. and Alberta have already begun to receive their first shipments of No Future gummies and Ontario is expected to receive its first shipments in September 2023 and be in stock at retailers by October 2023. No Future Vapes have been delivered in Alberta and are expected to land in Ontario on the same timeline as the gummies. Indiva plans for more regions and product launches to come online in the fall and winter of 2023.공시 • May 31Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth CorporationIndiva Limited announced that it has entered a non-brokered private placement of 37,230,000 common shares at a price of CAD 0.0579 per share for gross proceeds of CAD 2,155,617 on May 30, 2023. The transaction will include participation from new investor, Canopy Growth Corporation. The balance of the consideration will be paid by Canopy Growth Corporation to the company as additional consideration representing a value of CAD 844,383 and cash payment of CAD 1,250,000 on May 30, 2024. The private placement is expected to close on or before June 6, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The common shares to be issued under the private placement will have a hold period of four months and one day from the closing date.공시 • May 17Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023Indiva Limited provided revenue guidance for the second quarter of 2023. The company expects second quarter of 2023 net revenue to improve compared to the same period last year; however, there is risk that net revenue may decline sequentially, if sales of new products fail to offset lower sales of ingestible extracts as a result of Health Canada's recent order to stop production and sale of these products. Sequential growth in net revenue is expected to resume in the second half of 2023 driven by the introduction of new products in the third and fourth quarters, resulting primarily from in-house innovation. Gross margins are expected to continue to trend higher and benefit from the implementation of automation in the production and packaging of edible products.공시 • May 12Indiva Limited, Annual General Meeting, Jul 18, 2023Indiva Limited, Annual General Meeting, Jul 18, 2023.공시 • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023매출 및 비용 세부 내역Indiva가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:NDVA.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2437-411131 Dec 2338-511130 Sep 2336-712130 Jun 2334-912131 Mar 2335-1012131 Dec 2234-1113130 Sep 2234-1213130 Jun 2234-1613131 Mar 2235-1513131 Dec 2132-1511030 Sep 2130-1810030 Jun 2125-1510031 Mar 2119-168031 Dec 2015-158030 Sep 208-117030 Jun 205-106031 Mar 203-107031 Dec 191-119030 Sep 191-1110030 Jun 190-1010031 Mar 190-109031 Dec 180-97030 Sep 180-76030 Jun 180-65031 Mar 180-53031 Dec 170-32030 Sep 170-22030 Jun 170-22031 Mar 170-11031 Dec 160-110양질의 수익: NDVA.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: NDVA.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NDVA.F는 수익성이 없지만 지난 5년 동안 연평균 6.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 NDVA.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: NDVA.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: NDVA.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/09/09 01:52종가2024/06/12 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Indiva Limited는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Siddharth RajeevFundamental Research Corp.Rahul SarugaserRaymond James Ltd.Greg McLeishResearch Capital Corporation
공시 • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024
공시 • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
공시 • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023
공시 • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023
공시 • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023
공시 • Nov 06SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).SNDL Inc. (NasdaqCM:SNDL) enters into a stalking horse purchase agreement to acquire a remaining majority stake in Indiva Limited (TSXV:NDVA.H) for CAD 22.7 million on July 5, 2024. PricewaterhouseCoopers Inc. (The Monitor) currently estimates the value of the credit bid and cash consideration payable by SNDL under the Bid Agreement to be in the range of approximately CAD 25 million to CAD 28 million. As of July 8, 2024, the Court has approved the sale process. The Transaction is anticipated to close during SNDL's fourth quarter following the receipt of all such approvals. Indiva will seek approval for the Transaction from the Court on or about September 19, 2024. As per filing on August 29, 2024, stalking horse bid of SNDL has been chosen as the successful bid in the acquisition of Indiva. McCarthy Tétrault LLP is acting as legal counsel for SNDL, Bennett Jones LLP is acting as legal counsel for the Indiva Group, and Osler Hoskin & Harcourt LLP is acting as legal counsel for PricewaterhouseCoopers Inc. (the monitor). SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H) on November 4, 2024.
공시 • Jun 15Indiva Limited Announces Resignation of Rachel Goldman from the BoardIndiva announced that Rachel Goldman resigned from the board of Indiva on June 12, 2024, prior to the board resolving to commence proceedings under the CCAA.
공시 • May 24Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024Indiva Limited Provided Earnings Guidance for the second Quarter of 2024. For the quarter, the company expects net revenue will be higher on a sequential basis and year-over-year, expected to exceed $10 million, based on the strength of purchase orders from provincial wholesalers and deliveries to date in the quarter.
공시 • May 16Indiva Limited to Report Q1, 2024 Results on May 23, 2024Indiva Limited announced that they will report Q1, 2024 results Pre-Market on May 23, 2024
공시 • Apr 27Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024Indiva Limited Provided Earnings Guidance for the First Quarter and fiscal year 2024. For the quarter, the company expects net revenue will be lower on a sequential basis, primarily due to seasonality, and flat year-over-year, due to the continued growth in Pearls by Grön, and the contribution to revenue from No Future gummies and Indiva Blips offset by Wana converting to contract manufacturing and the loss of lozenge revenue.For the year, the company expects to generate record net revenue, driven by continued strength in its core brands, bolstered by new product introductions and continued efficiency gains at the production facility from automation and process improvements.
공시 • Apr 17Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024Indiva Limited announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
공시 • Feb 28Indiva Limited announced that it expects to receive CAD 4.312 million in fundingIndiva Limited announce a non-brokered private placement of up to 30,800,000 units at a price of CAD 0.14 per unit for aggregate gross proceeds of up to CAD 4,312,000 on February 28, 2024. Each unit will consist of one common share and one-half common share purchase warrant. Each warrant will be exercisable into one common share at a price of CAD 0.15 per common share for a period of 36 months from the date of issuance. The closing of the offerings may take place in one or more tranches. The offerings are subject to certain conditions including, but not limited to, the approval of the TSXV. The company may pay certain eligible finders a finder's fee of up to CAD 400,000.
공시 • Jan 22Indiva Limited announced that it expects to receive CAD 4 million in fundingIndiva Limited announces private placement of minimum of 20,000,000 units and maximum of 40,000,000 Units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 2,000,000 incase of minimum offering and CAD 4,000,000 incase of maximum offering on January 22, 2024. Each Unit consists of one common share and one-half Common Share purchase warrant. Each Warrant is exercisable into one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance. The Warrants will be governed by the terms and conditions set forth in the certificates representing the Warrants. The transaction is expected to close the final tranche closing will occur no later than March 7, 2024. The company will pay finder's cash fee 8% of the gross proceeds raised in respect of the Offering from subscribers and also issue to eligible finders such number of finder warrants equal to 8.0% of the number of Units sold under the Offering to subscribers introduced by such finders to the Company. The Finder Warrants, to the extent they are issued, shall entitle the holder thereof to acquire one Common Share at a price of CAD 0.15 per Common Share for a period of 36 months from the date of issuance.
공시 • Nov 22Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023Indiva Limited provided revenue guidance for fourth quarter of 2023. The company expects fourth quarter of 2023 net revenue, excluding contract manufacturing, to improve sequentially driven by new product introduction, including first full quarter of No Future sales across Canada. New SKUs coming to market include additional No Future gummies and vapes, Blips, as well as new 5-count and 25-count Pearls gummies. Gross margins are expected to continue to trend higher over time as the Company benefits from a mix shift to higher margin products and continues to achieve further production efficiencies driven by greater utilization of automation in production and packaging activities.
공시 • Nov 04Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023Indiva Limited announced that they will report Q3, 2023 results Pre-Market on Nov 21, 2023
공시 • Aug 18Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023Indiva Limited announced that they will report Q2, 2023 results Pre-Market on Aug 29, 2023
공시 • Aug 11Indiva Limited Launches No Future Gummies and VapesIndiva Limited introduced a new value-focused cannabis brand called No Future, which the Company has already begun shipping to B.C. and Alberta and is expected to ship to Ontario in September 2023. No Future is intended to fill a large and critical gap in the cannabis marketplace that opened once the ingestible extracts market was eliminated earlier this year. Indiva expects No Future to accelerate the migration of consumers from the illicit market to the legal market by drastically reducing the price per milligram of THC in cannabis edibles and other extract products such as vapes. No Future will initially launch with four flavours of THC gummies and three varieties of 1.2g 510 vapes. No Future THC Gummies will be 10mg THC per pack and retail prices are expected to reset the floor price of legal market gummies across Canada, with some stores selling at similar prices per mg of THC as ingestible extracts were sold. No Future Vapes will be sold in 1.2g 510 thread cartridges and introduced in three great-tasting strains: Sour Tangie (Sativa), Cherry Zlushie (Hybrid), and Hot CKS (Indica). Similar to No Future gummies, Indiva expects this set of products to reset the floor price of legal 1.2g vapes across Canada. B.C. and Alberta have already begun to receive their first shipments of No Future gummies and Ontario is expected to receive its first shipments in September 2023 and be in stock at retailers by October 2023. No Future Vapes have been delivered in Alberta and are expected to land in Ontario on the same timeline as the gummies. Indiva plans for more regions and product launches to come online in the fall and winter of 2023.
공시 • May 31Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth CorporationIndiva Limited announced that it has entered a non-brokered private placement of 37,230,000 common shares at a price of CAD 0.0579 per share for gross proceeds of CAD 2,155,617 on May 30, 2023. The transaction will include participation from new investor, Canopy Growth Corporation. The balance of the consideration will be paid by Canopy Growth Corporation to the company as additional consideration representing a value of CAD 844,383 and cash payment of CAD 1,250,000 on May 30, 2024. The private placement is expected to close on or before June 6, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The common shares to be issued under the private placement will have a hold period of four months and one day from the closing date.
공시 • May 17Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023Indiva Limited provided revenue guidance for the second quarter of 2023. The company expects second quarter of 2023 net revenue to improve compared to the same period last year; however, there is risk that net revenue may decline sequentially, if sales of new products fail to offset lower sales of ingestible extracts as a result of Health Canada's recent order to stop production and sale of these products. Sequential growth in net revenue is expected to resume in the second half of 2023 driven by the introduction of new products in the third and fourth quarters, resulting primarily from in-house innovation. Gross margins are expected to continue to trend higher and benefit from the implementation of automation in the production and packaging of edible products.
공시 • May 12Indiva Limited, Annual General Meeting, Jul 18, 2023Indiva Limited, Annual General Meeting, Jul 18, 2023.
공시 • May 04Indiva Limited to Report Q1, 2023 Results on May 16, 2023Indiva Limited announced that they will report Q1, 2023 results Pre-Market on May 16, 2023